Jun. 25 at 8:00 PM
$IONS
Big catalyst here.
Tryngolza just got FDA approval for severe hypertriglyceridemia, expanding from a tiny orphan indication into a ~3M patient market.
This is a major step-change: from niche rare disease asset → potential commercial cardiometabolic franchise.
Clinical data is strong (up to ~72% triglyceride reduction, lower pancreatitis risk), and importantly, it’s the first approved therapy in this indication with no direct competitor yet.
Market reaction (+3%) is still relatively muted compared to the size of the label expansion, which suggests the story may still be early in being repriced.
Now it shifts from “pipeline story” to real commercial execution.
